Want to join the conversation?
Geoff Meacham of Barclays asks about commercial formularies of ZEPATIER and what are the opportunities for expansion. $MRK said the company is pleased with the progress since the launch. The company also said that it feels great about potential access for 2017. On approaching the marketplace, $MRK is focusing on having access.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.